Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors - Top-Institutions - MDSpire

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • By

  • Ting-Kai Liao

  • Wei-Hsun Lu

  • Ping-Jui Su

  • Chih-Jung Wang

  • Ying Jui Chao

  • Yan-Shen Shan

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    single medical center
    single medical center

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    Maastricht University Medical Center
    Maastricht University Medical Center

    Maastricht, Limburg

    Key Differentiators

    • Oncology

  • #3

    University Hospital Wuerzburg
    University Hospital Wuerzburg

    Wuerzburg, Bavaria

    Key Differentiators

    • Oncology

  • #4

    Comprehensive Cancer Centre Mainfranken
    Comprehensive Cancer Centre Mainfranken

    Wuerzburg, Bavaria

    Key Differentiators

    • Oncology

  • #5

    University of Pittsburgh
    University of Pittsburgh

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Oncology

Original Source(s)

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • by Ting-Kai Liao, Wei-Hsun Lu, Ping-Jui Su, Chih-Jung Wang, Ying Jui Chao, Yan-Shen Shan

  • May 28, 2026

Related Content

Adjuvant radiotherapy for WHO grade II meningiomas: the unanswered question

Efficacy of Jishi Shuanghua Granules in preventing radiation-induced esophagitis in non-small cell lung cancer patients undergoing concurrent chemoradiotherapy: protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Radiomics-based interpretable machine learning model from multiphasic CT imaging for predicting pathological grade in upper tract urothelial carcinoma: a multicenter study